Call Us
267 354 2894
Spravato®
Brighter days ahead— an innovative approach to depression
Nurowav is now offering Spravato® esketamine nasal spray, the only FDA-approved nasal spray for depression
Spravato®
Brighter days ahead— an innovative approach to depression
Nurowav is now offering Spravato® esketamine nasal spray, the only FDA-approved nasal spray for depression
WHAT IS SPRAVATO®?
(esketamine nasal spray)
Nurowav is now offering Spravato® esketamine nasal spray, the only FDA-approved nasal spray for depression. Spravato® is a more specific form of ketamine designed to treat depression. Ketamine is a drug that’s primarily known for its uses as an anesthetic. You may have also heard of ketamine being used as a psychedelic street drug, but if it’s used under the supervision of a doctor, it can be perfectly safe.
Spravato® was FDA-approved in 2019 for people with depression who have not experienced adequate improvement with antidepressant medications.
Many major insurance companies cover esketamine nasal spray for depression.
A benefit of having treatment at a Nurowav treatment facility is that our team does all the work for you regarding insurance. We assist all patients with the coverage and reimbursement process.
During a Spravato® treatment, you may feel dizzy, or euphoric. Throughout your treatment, our team will be onsite to assist you.
After your two-hour session, you may be groggy and woozy. You will need to avoid hazardous activity for the remainder of the day. This includes operating a motor vehicle, so you will need someone to drive you home from treatment. By the next morning, most people are ready to resume their day with no restrictions.
Spravato® esketamine nasal spray for depression is now offered at select Nurowav treatment centers.
Spravato® must be given at a certified REMS (Risk Evaluation and Mitigation System) center. The medical staff at Nurowav’s certified treatment centers are trained to prescribe, dispense, and administer Spravato®, and we have established processes and procedures in accordance with the REMS program.
How to Get Started
No-cost consultation
Learn about Spravato® nasal spray
You will first talk with one of our intake specialists, who will collect some basic information and arrange a meeting with one of our Patient Care Coordinators. The Care Coordinator can meet with you in person or on the phone and will review your history and explain aspects of esketamine nasal spray treatment.
We focus on insurance so you don’t have to
Your Patient Care Coordinator will also explain treatment payment options and review standard insurance plan criteria with you. We will coordinate with your health insurance provider to determine benefits.
SHOULD I RECEIVE IV KETAMINE OR SPRAVATO® (NASAL ESKETAMINE)?
IV Ketamine
- Is not FDA-approved for the treatment of depression
- Is not covered by many insurance companies
- Is not offered at Nurowav
Esketamine nasal spray (Spravato®)
- Is FDA-approved for the treatment of depression
- Is covered by many insurance companies
- Is offered at Nurowav
Pre-assessment
Find out if Spravato® nasal spray is right for you
You will meet with a Nurowav provider for an evaluation, which includes questions about your history and symptoms.
If our provider has determined that you are a candidate for esketamine nasal spray and you are ready to move forward, they will create your individualized treatment plan.
Treatment
You’re ready to start feeling better!
At most Nurowav centers, we try to book your Spravato® treatments to accommodate your schedule, whether morning or afternoon appointments work best for you.
After you arrive at the center, you will be placed in a reclining chair where you can sit back and relax. You will be handed a nasal spray device to self-administer. Your care team will supervise you for at least two hours. Afterward, you will need someone to drive you home from treatment. By the next morning, most people are ready to resume their day with no restrictions.
Spravato® (esketamine) approved in the U.S. as the first and only monotherapy for adults with treatment-resistant depression
Following U.S. FDA Priority Review, approval is based on data demonstrating SPRAVATO® alone met its primary endpoint at 4 weeks and led to rapid and superior improvement in depressive symptoms compared to placebo as early as 24 hours1
1Janik A, Qiu X, Lane R, et al. SPRAVATO (esketamine nasal spray) as a monotherapy for treatment-resistant depression (TRD). American Society of Psychopharmacology Annual Meeting.; May 28-31, 2024. Poster W80.
HOW SPRAVATO®
WORKS
Take charge of your mental health
Don’t wait any longer to take control of your mental and physical health. Call or request and appointment online to speak with one of our Certified Care Coordinators about care and coverage.
OFFICE HOURS
402 Middletown Blvd, Ste 212
Langhorne, PA 19047
- 9am - 7:30pm
- 10am - 4pm
- closed